Orungal capsules are used in the treatment of mycoses, which are caused by a flora sensitive to the drug, it is used in the treatment of pityriasis versicolor, candidiasis with lesions of the mucous membrane and skin, dermatomycosis, fungal keratitis, deep visceral candidiasis and onychomycosis, which are caused by fungal fungi or fungal fungi.
Orungal composition and form of release
Manufactured in capsules. The active substance of the drug is itraconazole.
Orungal capsules are used in the treatment of mycoses, which are caused by a flora sensitive to the drug, it is used in the treatment of pityriasis versicolor, candidiasis with lesions of the mucous membrane and skin, dermatomycosis, fungal keratitis, deep visceral candidiasis and onychomycosis, which are caused by fungal fungi or fungal fungi. Orungal has proven itself in the treatment of systemic mycoses, such as blastomycosis, sporotrichosis, systemic candidiasis, systemic aspergillosis, paracoccidioidomycosis, cryptococcosis, histoplasmosis, as well as other tropical and systemic mycoses.
An absolute contraindication to use is hypersensitivity to its components. In addition to this, the drug cannot be used in joint therapy with ergot alkaloids, midazolam, triazolam, as well as drugs metabolized with the participation of the CYP3A4 enzyme and capable of increasing the QT interval. It is also recommended to abandon the joint use of the drug with HMG-CoA reductase inhibitors, which are metabolized with the participation of the CYP3A4 enzyme.
Relative contraindications to the appointment of Orungal are childhood, chronic heart failure, cirrhosis of the liver, chronic renal failure, hypersensitivity to drug components.
Application during pregnancy and lactation
The use of lactating and pregnant women in therapy is justified only if the patient suffers from systemic mycoses that threaten her life.
Method of administration and dosage
Orungal capsules are taken after meals. The dosage regimen is selected based on the type of disease: in the treatment of dermatomycosis of smooth skin, the patient receives 200 mg once a day for 7 days, vulvovaginal candidiasis 200 mg twice a day for 1 day or 200 mg once a day for three days, pityriasis lichen – 200 mg once a day for a week, oral candidiasis – 100 mg once a day, the duration of treatment is 15 days.
When treating candidiasis of the oral mucosa or esophagus, take in one or two doses of 200 mg per day, the duration of therapy is 7 days, if necessary, the duration of treatment can be doubled. To prevent the development of systemic fungal infections, the patient is prescribed 5 mg per kg of body twice a day. The use of the drug should be started 7 days before the start of cytostatic therapy or 7 days after bone marrow transplantation. Treatment continues until the number of neutrophils is restored.
No cases of drug overdose have been recorded. When taking the drug in high doses, the patient is prescribed gastric lavage and the intake of enterosorbents.
When taking the drug, patients develop anorexia, epigastric pain, dyspepsia, hepatitis, toxic liver damage, headaches, dizziness, peripheral neuropathy, angioedema, allergic reactions, alopecia, photosensitivity, dysmenorrhea, pulmonary edema.
Storage conditions and periods
Orungal is stored in places protected from the penetration of children at a temperature of no more than 30 degrees. The drug should be stored no more than 3 years from the date of manufacture.